I would just add to look for countries that have a sophisticated negotiation capacity, which can actually negotiate value-added deals.
We heard Dr. Eyolfson talk about adherence challenges, and keeping people on the medicines. There are systems for negotiating that into these contracts that go beyond the price-volume agreements. Especially for drugs for rare or really complex disorders, I'd look to Italy.
Germany has a very good system for stepwise negotiations. There's a set of six. You're expected to come to a deal at the end.
Figure out the ones that actually work best for all of the vulnerable populations and not just for the working poor, as you've called them. Let's talk about the people with rare disorders as well, and some of the smaller patient populations.